Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
Mario Castro, MD, MPH
Study ID
NCT04624490
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Asthma
  • COPD
  • Cystic Fibrosis
  • Interstitial Lung Disease
  • Other Lung Disease
  • Pulmonary Hypertension
  • Pulmonary Infection

Eligibility Criteria

Sex
ALL
Age
3 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Hyperpolarized Xe129 — DRUG
    During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.

Study Details

The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

Key Dates

Start date
Nov 2, 2020
Status verified
Apr 2026
Primary completion
Oct 26, 2028
Completion
Oct 26, 2028

Study Design

Enrollment
260 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Hyperpolarized 129Xe
    Administration of hyperpolarized xenon during MRI (up to 1L doses) to develop imaging methods and assess pulmonary function in adults.

Primary Outcome Measure

RBC/Barrier Ratio [ Time Frame: Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityKansas66160
Peter J Niedbalski, PhD
[email protected]
9135882271

Find similar trials in Kansas City, KS

By condition
AsthmaCOPD
By specialty
PulmonologyLung disease
By research site
University of Kansas Medical Center· Kansas City, KS

Related Studies